Literature DB >> 20585321

Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity.

L-O Atchaneeyasakul1, A Trinavarat.   

Abstract

In recent times, laser treatment combined with intravitreal bevacizumab (Avastin) has been used rarely as early investigations to treat patients with aggressive posterior retinopathy of prematurity (ROP). We describe choroidal ruptures that were documented at 10 weeks after this combined treatment in a preterm infant born at 28 weeks gestation with a birth weight of 1190 g. Aggressive posterior ROP was diagnosed at the age of 6 weeks. Initial treatment included bilateral laser ablation, followed immediately by intravitreal bevacizumab (IVB, 0.75 mg) in the right eye. On day 5, a remarkable regression of plus sign and fibrovascular proliferation was noted only in the right eye. At this point, additional laser treatment combined with IVB was given in the left eye, which dramatically resolved plus disease and neovascularization. At 10 weeks after IVB in the left eye, two sites of choroidal ruptures were revealed along the posterior edges of laser scars. There was no evidence of choroidal neovascularization associated with the choroidal ruptures. Choroidal rupture may occur shortly after laser ablation plus IVB treatment for aggressive posterior ROP. This occurrence requires recognition to determine whether it is actually related to the treatment. Long-term follow-up is important for understanding the nature and progression of this potentially serious complication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20585321     DOI: 10.1038/jp.2009.166

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  10 in total

1.  Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I.

Authors:  T R Padhi; T Das; S Rath; L Pradhan; S Sutar; K G Panda; R Modi; S Jalali
Journal:  Eye (Lond)       Date:  2015-11-20       Impact factor: 3.775

Review 2.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

3.  [Pharmacological treatment for retinopathy of prematurity].

Authors:  A Stahl; H Agostini; C Jandeck; W Lagrèze
Journal:  Ophthalmologe       Date:  2011-08       Impact factor: 1.059

4.  SiRNA silencing of VEGF, IGFs, and their receptors in human retinal microvascular endothelial cells.

Authors:  Yona Nicolau; Fayez Bany-Mohammed; Charles L Cai; Jacob V Aranda; Kay D Beharry
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

5.  Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety.

Authors:  Fen Tang; Michelle E LeBlanc; Weiwen Wang; Dan Liang; Ping Chen; Tsung-Han Chou; Hong Tian; Wei Li
Journal:  Angiogenesis       Date:  2019-01-14       Impact factor: 9.596

6.  Use of intravitreal anti-VEGF: retinopathy of prematurity surgeons' in Hamlet's dilemma?

Authors:  Rajvardhan Azad; Vivek Dave; Subhadra Jalali
Journal:  Indian J Ophthalmol       Date:  2011 Nov-Dec       Impact factor: 1.848

Review 7.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

8.  Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Intermittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy.

Authors:  Jeffrey J Tan; Charles L Cai; Eric M Shrier; Lois McNally; Douglas R Lazzaro; Jacob V Aranda; Kay D Beharry
Journal:  J Ophthalmol       Date:  2017-07-09       Impact factor: 1.909

Review 9.  Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies.

Authors:  Chang Dai; Keith A Webster; Amit Bhatt; Hong Tian; Guanfang Su; Wei Li
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923

10.  Progressive symmetric vertical macular wide angioid streak-like lacquer crack.

Authors:  Ahmad M Mansour
Journal:  Int Med Case Rep J       Date:  2016-04-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.